EMA Withdrawn: Sustiva (efavirenz) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

Sustiva (efavirenz) has been withdrawn from the EU market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Sustiva (efavirenz)

Snippet

Status: Withdrawn. Therapeutic area: HIV Infections. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 23/05/2023